The Dabigatran debate
- PMID: 25763378
- PMCID: PMC4352680
- DOI: 10.5339/gcsp.2014.41
The Dabigatran debate
References
-
- Kaba RA, Camm AJ, Williams TM, Sharma R. Managing atrial fibrillation in the global community: The European perspective. Glob Cardiol Sci Pract. 2013;2013(2):173–184. doi:10.5339/gcsp.2013.24. - DOI - PMC - PubMed
-
- Al-Kindi S. Lack of reversibility for NOACs. Glob Cardiol Sci Pract. 2014;2014(1):1. doi:10.5339/gcsp.2014.1. - DOI - PMC - PubMed
-
- Kaba RA, Ahmed O, Cannie D. Response to “Lack of reversibility for NOACs.”. Glob Cardiol Sci Pract. 2014;2014(1):2. doi:10.5339/gcsp.2014.2. - DOI - PMC - PubMed
-
- Boehringer Ingelheim. Dabigatran etexilate recommended for approval in atrial fibrillation for stroke prevention in Europe http://www.boehringer-ingelheim.ca/en/news/press_releases/2011/15_april_....
-
- Charlton B, Redberg R. The trouble with dabigatran. BMJ. 2014 Jul 23;349:g4681. doi: 10.1136/bmj.g4681. - DOI - PubMed
LinkOut - more resources
Full Text Sources